ViforPharma

News

Reuters - 2 months ago

Australian shares see broad gains, U.S. inflation data in focus

Australian shares see broad gains, U.S. inflation data in focus Feb 14 (Reuters) - Australian shares climbed on Tuesday, lifted by hopes around U.S. inflation data due later in the day, which could influence the Federal Reserve's monetary policy path. The S&P/ASX 200 index .AXJO rose 0.7% to 7,466.9 by 2341 GMT, amid gains across all sectors. The benchmark had declined 0.2% on Monday.

Reuters - 2 months ago

Australian biotech CSL profit jumps on post-lockdown revival

UPDATE 2-Australian biotech CSL profit jumps on post-lockdown revival Blood plasma unit profit down 6.25% Vaccines unit profit up 9% Shares up 1% Recasts and writes through, adds analyst quote and shares By Byron Kaye and Archishma Iyer Feb 14 (Reuters) - Australian biotech giant CSL Ltd CSL.AX said on Tuesday its first-half profit jumped 10%, beating analyst estimates, as a resurgence in blood plasma donations enabled it to boost sales and more people got vaccinated against influenza.

Reuters - 10 months ago

EU regulators investigate Vifor Pharma over anti-competitive behaviour

By Foo Yun Chee BRUSSELS, June 20 (Reuters) - EU antitrust regulators are investigating whether Vifor Pharma VIFN.S , which is being acquired by CSL Ltd CSL.AX , disparaged its rival Pharmacosmos in order to hinder competition to its blockbuster iron medicine Ferinject. The European Commission, which opened the probe on Monday, said it has indications of this behaviour going on for many years, which may be in breach of EU rules against companies abusing their dominant position.

Reuters - 10 months ago

EU antitrust regulators to probe if Vifor Pharma disparages rival

BRUSSELS, June 20 (Reuters) - EU antitrust regulator on Monday launched an investigation into possible anti-competitive disparagement by Vifor Pharma VIFN.S of its closest rival Pharmacosmos in an apparent attempt to hinder competition against its iron medicine. The European Commission said it has indications of this behaviour going on for many years.

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.